Post-Market Clinical Follow-up of Intra-Articular Hyaluronic Acid in Hip Osteoarthritis
Key facts
- Where
- Madrid and Zaragoza, SpainSee the 3 sites
Where in Spain
- Hospital Universitario de la PrincesaMadrid, SpainContact: Dr. J Del RíoTaking people
- QuironSalud. Hospital Juan BravoMadrid, SpainContact: Dr. J Del RíoTaking people
- Hospital Provincial Nuestra Señora de GraciaZaragoza, SpainContact: Dr. A SantamaríaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Meiji Pharma Spain S.A.
- Trial code
- NCT07883395
- Record updated
- 12 November 2026
- Original description
The study population consists of approximately 40 adult outpatients aged 40 years or older with symptomatic hip osteoarthritis of at least 1 year of clinical evolution, treated with intra-articular hyaluronic acid in routine clinical practice within the Traumatology and Rehabilitation departments of participating hospitals in Spain.Read full original descriptionShow less
Clinical Follow-up Study of Patients With Hip Osteoarthritis Treated With Intra-Articular Hyaluronic Acid
The study population consists of approximately 40 adult outpatients aged 40 years or older with symptomatic hip osteoarthritis of at least 1 year of clinical evolution, treated with intra-articular hyaluronic acid in routine clinical practice within the Traumatology and Rehabilitation departments of participating hospitals in Spain.
Inclusion: Age: >40 years at the time of study inclusion; Preserved gait capability, with or without assistive devices; Symptomatic hip arthropathy with a disease evolution of at least 1 year; Radiographic Kellgren-Lawrence grade II-III documented within the 12 months prior to study entry; Total Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) score >15; Patient currently receiving intra-articular hyaluronic acid treatment within 3 months prior to study inclusion.
Exclusion: Presence of other chronic or autoimmune diseases that could interfere with clinical evaluation; History of hypersensitivity or allergy to hyaluronic acid or its derivatives; Prior administration of intra-articular platelet-rich plasma (PRP) or intra-articular corticosteroids within 3 months, or intra-articular hyaluronic acid within 6 months prior to study entry; Refusal to provide written informed consent; Females who are pregnant, breastfeeding, or not using effective contraception; Body Mass Index (BMI) ≥ 30 kg/m².